SCHEMBL10133067

SCHEMBL10133067

O=S(=O)(CCc1ccccc1)Cc1ccc(-c2ccccc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 4/20 0.65
MMP12 P39900 3/20 0.65
CA2 P00918 3/20 0.53
MMP8 P22894 1/20 0.51
FFAR1 O14842 1/20 0.47
MEN1 O00255 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47
MMP1 P03956 1/20 0.45
MMP2 P08253 1/20 0.45
MMP3 P08254 1/20 0.45
MMP7 P09237 1/20 0.45
MMP9 P14780 1/20 0.45
ACLY P53396 1/20 0.44
FDFT1 P37268 1/20 0.44
CA1 P00915 2/20 0.44
CA9 Q16790 2/20 0.44
FAAH O00519 1/20 0.44
PRSS1 P07477 1/20 0.44
PRSS2 P07478 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3247748 0.90 CA2 (0.62) MMP13MMP12CA2MMP8MEN1
SCHEMBL302785 0.80 CA2 (0.69) MMP13MMP12CA2MMP8MMP1
SCHEMBL10133090 0.79 MMP12 (0.50) MMP13MMP12CA2MMP8FFAR1
SCHEMBL15686580 0.79 CA2 (0.65) CA2MEN1HTTKMT2ACA1
SCHEMBL31540567 0.77 MMP12 (0.59) MMP13MMP12CA2MMP8FFAR1
SCHEMBL8600793 0.77 MMP12 (0.64) MMP13MMP12CA2MMP8FFAR1
SCHEMBL31540566 0.77 MMP12 (0.59) MMP13MMP12CA2MMP8FFAR1
SCHEMBL7829131 0.77 MMP12 (0.59) MMP13MMP12CA2MMP8FFAR1
SCHEMBL14495267 0.76 CA2 (0.77) MMP13MMP12CA2MMP8MMP1
SCHEMBL29007589 0.76 MMP13 (0.57) MMP13MMP12CA2MMP8KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 US disclosed
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
WO-2009009041-A2 COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE KINEX PHARMACEUTICALS, LLC (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149510-A1 Compositions and methods for modulating a kinase cascade MAP3K6, MAP3K4, MAP3K3 MMP13 2938/4885MMP12 2860/4885CA2 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.